|89.02||+1.02||+1.16%||Vol 6.84M||1Y Perf 22.64%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||0.01 0.01%|
|Target Price||96.07||Analyst Rating||Moderate Buy 1.79|
|Potential %||7.92||Finscreener Ranking||★★★ 50.88|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 52.18|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 73.76|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||55.37B||Earnings Rating||Sell|
|Price Range Ratio 52W %||88.16||Earnings Date||20th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||20th Apr 2021|
|Estimated EPS Next Report||0.47|
|EPS Growth Next 5 Years %||15.70|
|Avg. Weekly Volume||2.05M|
|Avg. Monthly Volume||2.53M|
|Avg. Quarterly Volume||2.65M|
Edwards Lifesciences Corporation (NYSE: EW) stock closed at 89.02 per share at the end of the most recent trading day (a 1.16% change compared to the prior day closing price) with a volume of 6.86M shares and market capitalization of 55.37B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 14900 people. Edwards Lifesciences Corporation CEO is Michael A. Mussallem.
The one-year performance of Edwards Lifesciences Corporation stock is 22.64%, while year-to-date (YTD) performance is -2.42%. EW stock has a five-year performance of 150.64%. Its 52-week range is between 66.23 and 92.08, which gives EW stock a 52-week price range ratio of 88.16%
Edwards Lifesciences Corporation currently has a PE ratio of 65.20, a price-to-book (PB) ratio of 11.44, a price-to-sale (PS) ratio of 16.39, a price to cashflow ratio of 50.40, a PEG ratio of 2.32, a ROA of 11.52%, a ROC of 16.30% and a ROE of 18.12%. The company’s profit margin is 15.28%, its EBITDA margin is 23.70%, and its revenue ttm is $3.26 Billion , which makes it $5.24 revenue per share.
Of the last four earnings reports from Edwards Lifesciences Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.47 for the next earnings report. Edwards Lifesciences Corporation’s next earnings report date is 20th Apr 2021.
The consensus rating of Wall Street analysts for Edwards Lifesciences Corporation is Moderate Buy (1.79), with a target price of $96.07, which is +7.92% compared to the current price. The earnings rating for Edwards Lifesciences Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Edwards Lifesciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Edwards Lifesciences Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 8.12, ATR14 : 2.34, CCI20 : 137.84, Chaikin Money Flow : 0.15, MACD : 0.34, Money Flow Index : 87.33, ROC : 7.45, RSI : 53.58, STOCH (14,3) : 98.61, STOCH RSI : 1.00, UO : 59.66, Williams %R : -1.39), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Edwards Lifesciences Corporation in the last 12-months were: Donald E. Bobo (Option Excercise at a value of $2 385 699), Donald E. Bobo (Sold 173 330 shares of value $15 337 791 ), Huimin Wang (Option Excercise at a value of $1 905 050), Huimin Wang (Sold 124 407 shares of value $10 761 691 ), Jean-Luc M. Lemercier (Option Excercise at a value of $1 022 570), Jean-Luc M. Lemercier (Sold 70 556 shares of value $6 554 133 ), Katie Szyman (Option Excercise at a value of $680 235), Katie Szyman (Sold 49 946 shares of value $4 290 261 ), Larry L. Wood (Option Excercise at a value of $2 879 587), Larry L. Wood (Sold 108 400 shares of value $9 460 284 ), Michael A. Mussallem (Option Excercise at a value of $14 952 827), Michael A. Mussallem (Sold 708 350 shares of value $59 743 592 ), Nicholas J. Valeriani (Option Excercise at a value of $469 304), Nicholas J. Valeriani (Sold 8 200 shares of value $698 752 ), Robert W.A. Sellers (Option Excercise at a value of $468 710), Robert W.A. Sellers (Sold 21 540 shares of value $1 779 160 ), Scott B. Ullem (Option Excercise at a value of $4 378 440), Scott B. Ullem (Sold 239 400 shares of value $18 728 867 ), Steven R. Loranger (Option Excercise at a value of $696 789)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.